The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)

The Law Offices of Frank R. Cruz announces an investigation on behalf of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On May 15, 2020, the Company announced that it had discovered an antibody which “demonstrated 100% inhibition of SARS-CoV-2 virus infection” and which Sorrento’s CEO called a “cure.”

On this news, Sorrento’s share price rose more than 280%.

Then, on May 20, 2020, Hindenburg Research called the Company’s claims “too good to be true.” In a report citing former Sorrento employees, Hindenburg Research alleged that it was “too early” to tell whether the Company had found a cure and that "Sorrento's actions are manipulative at the worst possible time and simply amount to an attempt to shamelessly profiteer off the pandemic."

On this new, the Company’s share price fell $0.67 per share, or over 11%, to close at $5.03 per share on May 21, 2020.

Then, on May 22, 2020, BioSpace published an article in which Sorrento’s CEO “insist[ed] that [he] did not say it was a cure.”

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Sorrento securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067, at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005964/en/